- Home
- EXEL vs TMQ Comparison
EXEL vs TMQ Comparison
Compare EXEL & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- TMQ
- Stock Information
- Founded
- EXEL 1994
- TMQ 2004
- Country
- EXEL United States
- TMQ Canada
- Employees
- EXEL N/A
- TMQ N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- TMQ Precious Metals
- Sector
- EXEL Health Care
- TMQ Basic Materials
- Exchange
- EXEL Nasdaq
- TMQ Nasdaq
- Market Cap
- EXEL 9.8B
- TMQ N/A
- IPO Year
- EXEL 2000
- TMQ N/A
- Fundamental
- Price
- EXEL $36.17
- TMQ $1.60
- Analyst Decision
- EXEL Buy
- TMQ
- Analyst Count
- EXEL 18
- TMQ 0
- Target Price
- EXEL $37.59
- TMQ N/A
- AVG Volume (30 Days)
- EXEL 2.2M
- TMQ 501.3K
- Earning Date
- EXEL 05-13-2025
- TMQ 04-02-2025
- Dividend Yield
- EXEL N/A
- TMQ N/A
- EPS Growth
- EXEL 170.77
- TMQ N/A
- EPS
- EXEL 1.76
- TMQ N/A
- Revenue
- EXEL $2,168,701,000.00
- TMQ N/A
- Revenue This Year
- EXEL $5.78
- TMQ N/A
- Revenue Next Year
- EXEL $10.94
- TMQ N/A
- P/E Ratio
- EXEL $20.64
- TMQ N/A
- Revenue Growth
- EXEL 18.50
- TMQ N/A
- 52 Week Low
- EXEL $20.14
- TMQ $0.39
- 52 Week High
- EXEL $40.26
- TMQ $2.09
- Technical
- Relative Strength Index (RSI)
- EXEL 43.89
- TMQ 52.11
- Support Level
- EXEL $34.90
- TMQ $1.59
- Resistance Level
- EXEL $40.26
- TMQ $1.70
- Average True Range (ATR)
- EXEL 1.21
- TMQ 0.10
- MACD
- EXEL -0.19
- TMQ 0.00
- Stochastic Oscillator
- EXEL 23.69
- TMQ 72.00
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.